Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Aclarion Inc

ACON:NAQ

Aclarion Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.177
  • Today's Change0.001 / 0.51%
  • Shares traded99.40k
  • 1 Year change-97.01%
  • Beta--
Data delayed at least 15 minutes, as of Sep 24 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.

  • Revenue in USD (TTM)53.95k
  • Net income in USD-5.90m
  • Incorporated2008
  • Employees6.00
  • Location
    Aclarion Inc8181 Arista Place, Ste 100BROOMFIELD 80021United StatesUSA
  • Phone+1 (650) 241-1740
  • Fax+1 (302) 636-5454
  • Websitehttps://aclarion.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Regen BioPharma Inc236.57k-882.60k1.22m1.00------5.15-0.2157-0.21570.0594-1.181.04--3.82236,570.00-407.33-104.36---------392.01-275.00---1.36----0.441618.79-58.11------
GRI Bio Inc0.00-8.28m1.35m4.00--0.0782-----100.69-100.690.005.880.00----0.00-130.64-192.93-187.01-353.99-------37,650.49----0.00-------85.61--29.46--
Aclarion Inc53.95k-5.90m1.60m6.00--0.885--29.64-4.74-4.740.01460.200.0212--3.598,991.67-231.70---714.18---51.53---10,937.05-----111.150.3212--24.75--34.38------
Panbela Therapeutics Inc0.00-28.56m1.65m7.00---------84.64-84.640.00-2.180.00----0.00-197.23-215.89-3,522.07-476.38-----------143.57--------27.68------
Hi-Great Group Holding Co71.99k-74.35k1.78m--------24.73-0.0007-0.00070.0007-0.00130.71490.627-----73.83------51.28---103.28--0.0099-20.74-----47.32---3,789.70------
Pharmagreen Biotech Inc4.36k-403.84k1.83m0.00------418.58-0.0007-0.00070.00001-0.00340.03660.22747.33---339.07-523.11----54.36---9,263.30-307,598.300.0004-2.15--------35.03------
Axim Biotechnologies Inc92.90k-4.14m1.89m6.00------20.31-0.0163-0.01630.0003-0.03240.0233----15,483.33-103.73-154.34---390.7316.94---4,451.97-36,362.71---3.14----345.05-27.38-29.10------
180 Life Sciences Corp0.00-12.55m1.92m4.00---------28.16-28.160.00-0.44390.00----0.00-142.80-42.39-270.23-56.41------------18.20------48.52------
Novelstem International Corp18.00k-1.65m1.97m15.00------109.39-0.0352-0.03520.0004-0.05410.0081--8.00---63.77-----------7,867.33-----2.132.61--0.00---446.84------
Dermata Therapeutics Inc0.00-9.82m1.97m8.00--0.3134-----19.42-19.420.004.790.00----0.00-140.74---173.01--------------0.00------18.90------
Cyclacel Pharmaceuticals Inc80.00k-17.61m2.03m12.00--1.86--25.42-16.14-16.140.04230.55340.0065--0.0547---142.14-57.58-327.21-69.81-----21,882.50-18,789.29---100.520.00----22.87-6.34---31.23--
ELEVAI Labs Inc2.47m-4.75m2.08m18.00--0.7372--0.8409-0.2698-0.26980.14080.13970.72491.0495.33137,407.20-139.23---285.65--69.25---192.08--0.5439--0.00--123.50---138.94------
Data as of Sep 24 2024. Currency figures normalised to Aclarion Inc's reporting currency: US Dollar USD

Institutional shareholders

2.59%Per cent of shares held by top holders
HolderShares% Held
CapFinancial Partners LLCas of 31 Mar 202498.44k1.20%
Geode Capital Management LLCas of 30 Jun 202442.06k0.51%
HRT Financial LLCas of 31 Mar 202428.64k0.35%
Citadel Securities LLCas of 31 Mar 202424.85k0.30%
Ground Swell Capital LLCas of 30 Jun 202412.95k0.16%
Tower Research Capital LLCas of 31 Mar 20245.37k0.07%
BofA Securities, Inc.as of 31 Mar 2024100.000.00%
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 202414.000.00%
Two Sigma Securities LLCas of 31 Mar 20240.000.00%
SSgA Funds Management, Inc.as of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.